Struggling Norwegian Air gets a lift from bank stake sale
By Terje Solsvik and Victoria Klesty OSLO (Reuters) - Norwegian Air has agreed to sell its stake in banking company Norwegian Finans Holding for 2.22 billion crowns ($246.7 million), boosting the loss-making airline's finances and sending its shares sharply higher on Monday. Norwegian Finans Holding owns Bank Norwegian, a credit card company originally set up by Norwegian Air. The airline is selling its 17.5% stake to Cidron Xingu Limited, indirectly controlled by Nordic Capital Fund IX and Sampo
By Terje Solsvik and Victoria Klesty
OSLO (Reuters) - Norwegian Air has agreed to sell its stake in banking company Norwegian Finans Holding for 2.22 billion crowns ($246.7 million), boosting the loss-making airline's finances and sending its shares sharply higher on Monday.
Norwegian Finans Holding owns Bank Norwegian, a credit card company originally set up by Norwegian Air. The airline is selling its 17.5% stake to Cidron Xingu Limited, indirectly controlled by Nordic Capital Fund IX and Sampo.
The deal will boost Norwegian Air's cash holdings by 934 million crowns and lead to an accounting gain of 196 million.
The European aviation sector has been struggling with overcapacity, leading some airlines to offer loss-making fares and a few smaller carriers to go bust.
"The sale of the NOFI shares is part of Norwegian's strategy to strengthen our core airline operations and focus on the transition from growth to profitability," Norwegian Air's acting Chief Executive Geir Karlsen said in a statement.
While the deal could help the airline refinance a 250 million euro ($277.6 million) bond maturing in December, some analysts said the company may need to raise more cash from shareholders at a later time.
Norwegian late last year set out plans to slash costs and focus on short-term profitability over long-term growth, but has been hampered by the worldwide grounding of the Boeing 737 MAX aircraft, of which the company has 18 in its fleet.
While the airline's earnings per passenger rose during the important early summer months, the increase was smaller than most analysts had anticipated, hitting the company's share price.
"Without an ongoing sustained improvement in the unit revenue position or unit cost position of the business, we struggle to see how the company can get through the next 9 months without needing to return to capital markets for additional equity," Bernstein analysts said in a research note.
Bernstein has an 'underperform' rating on Norwegian Air shares with a target price of 10 crowns.
The NOFI shares were sold at 68 crowns each, a 15.4% premium to Friday's close of 58.90 crowns.
Norwegian Air's shares were up 5.8% to 33.4 crowns at 0825 GMT, off an early high of 36 crowns. Norwegian Finans was up 16.1% at 68.40 crowns.
"The buyers, Sampo and Nordic Capital, already own consumer lender Nordax and have earlier said they will seek consolidation in the industry," said DNB Markets, which has 'buy' ratings on both the airline and Norwegian Finans.
(Editing by Gwladys Fouche and Mark Potter)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
WARSAW (Reuters) - Polish prosecutors said on Saturday they had brought fraud charges against a prominent lawyer and former deputy prime minister who is a vocal critic of the government, and prohibited him from leaving Poland or practising law. Prosecutors also denied mistreating Roman Giertych, who fainted during his detention on Thursday and is currently defending billionaire bank owner Leszek Czarnecki, a thorn in the government's side who is suspected of cheating clients of his Idea Bank.
By Timothy Gardner WASHINGTON (Reuters) - U.S.
MOSCOW (Reuters) - The Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories Ltd have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine, the sovereign wealth fund said on Saturday. Large-scale trials of the Sputnik V vaccine in India were first announced and then knocked back by Indian regulators, who said the scale of Phase I and II trials conducted in Russia earlier this year was too small, requesting that they be repeated.